Trial Profile

A Phase 1, Dose-finding Study of Debio 0123 as Monotherapy in Adult Patients With Advanced Solid Tumors, Followed by an Expansion Part to Assess Safety and Preliminary Anti-tumor Activity

Status: Active, no longer recruiting

Phase of Trial: Phase I

Latest Information Update: 04 Nov 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Debio 0123 (Primary)
Indications Carcinoma; Endometrial cancer; Fallopian tube cancer; Gynaecological cancer; Peritoneal cancer; Solid tumours
Focus Adverse reactions; Therapeutic Use
Sponsors Debiopharm

31 Oct 2025 Status changed from recruiting to active, no longer recruiting.
29 May 2025 According to a Debiopharm media release, data from this trial will be presented at the 2025 Annual American Society of Clinical Oncology (ASCO) Meeting in Chicago, Illinois.
04 Jun 2024 Results(As of October 24, 2023, n=27 pts) evaluating Safety, pharmacokinetic, and preliminary antitumor activity of Debio 0123 as monotherapy, presented at the 60th Annual Meeting of the American Society of Clinical Oncology

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com